Our experience speaks for itself
F-star Therapeutics
Undertaking:
Helped F-star establish a foundation in the UK
CSO role
Established antibody technology
Dr Beatriz Goyenechea played a key role in the foundation of the UK branch of the Austrian founded company F-Star. This included facility location, hiring, company operations, equipment procurement, due diligence and platform technology development. Dr. Moulder served as the CSO, where he established the company’s bispecific antibody technology and led the translational efforts to identify its first clinical lead.
News / Articles / Press Release:
Antibody Engineering Company F-Star Opens Second Research Site in Cambridge, UK
Merck Serono and F-Star to Collaborate in the Discovery and Development of Novel Targeted Biologics
F-star, Merck Agree Up to €1B Deal to Develop Five Bispecific Anticancer Antibodies
F-star agrees antibody deal worth a potential €1.3M with Boehringer Ingelheim
Tusk Therapeutics
Undertaking:
Discovery and development of CD25 antibody
Research and development
Leadership
At Tusk, Dr Moulder and Dr Goyenechea directed the discovery and development of the anti-CD25 antibody which showed anticancer activity by depleting Tregs while preserving IL-2 activity on effector T cells, which subsequently prompted Tusk’s acquisition by Roche.
News / Articles / Press Release:
Roche Focuses on T Regulatory Cells in $758 Million Acquisition of Tusk Therapeutics
Black Belt Therapeutics
Undertaking:
Due diligence
Discovery and validation
After the successful acquisition of Tusk Therapeutics by Roche, Black Belt Therapeutics spined out to pursue and expand oncology candidates in Tusk’s pipeline. Dr Beatriz Goyenechea, as Director of Therapeutic Discovery, focused in consolidating existing assets for alliances, scientific due diligence and target discovery and validation. Black Belt successfully licenced out to CASI Pharmaceuticals a novel anti CD38 antibody which is expected to begin its clinical study in 2021.
News / Articles / Press Release:
Black Belt Therapeutics spins out of Tusk concurrent with acquisition by Roche
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program
About Anti-CD38 Monoclonal Antibodies
Biogen
Undertaking:
Director Bioassay/predictive medicine
CMC leader, FDA representative Antova
CMC leader, FDA/EMEA representative Amevive
Dr Kevin Moulder took over leadership of an 80 employee department responsible for preclinical and clinical PK, antigenicity, potency and characterization assay development and validation. He introduced predictive medicine to the company. Amongst other programs, he was involved in the Avonex BLA and also appointed CMC leader and represented the company at FDA and EMEA meetings for two antibody programs.
News / Articles / Press Release:
Domantis
Undertaking:
Vice president, Research & Development
Vice president, Development
Established single domain antibody technology
Development pipeline of 10+ novel single domain leads
Took lead through to successful IND filing
Key role in board meetings, SAB meetings and investor meetings/due diligence
News / Articles / Press Release:
GlaxoSmithKline to Acquire Domantis for £230 Million
PharmaTimes - GlaxoSmithKline acquires Domantis for £230 million
